Taj Worldwide | Taj Group | Media | Career | FAQs | Feedback | contact us
 
Taj Logo
especially Products
 
Quality Medicines Api Generic Manufacturing For Doctors Brands Newsroom
 

Lincozin

 
HOME >> PRODUCTS >> Taj Products >> Lincozin
Taj  ALL Products View Products According to Category


Each capsule contains
Composition

Lincomycine Hydrochoride I.P .........................................250 mg
equivalent to Lincomycin base.........................................250 mg

Indications
Lincomycin has been used in the treatment of serious skin infections caused by susceptible strains of streptococci, pneumococci, and staphylococci.

Description and Clinical Pharmacology
The mode of action of lincomycin is the inhibition of protein synthesis by the inhibition of the binding of aminoacyl sRNA to the messenger ribosome complex at the 50S ribosomal unit.

Lincomycin is absorbed rapidly after oral administration, reaching peak levels in 2 to 4 hours. Levels above the minimum inhibitory concentration for most gram-positive organisms are maintained for 6 to 8 hours. I.M. administration of lincomycin produces peak serum levels in 30 minutes with detectable levels persisting for 24 hours after a 600 mg dose.

I.V. infusions of lincomycin over a 2 hour interval yield therapeutic levels for 14 hours.

Precautions
General: Should be used with caution in those patients with a history of gastrointestinal disease, specifically colitis.

Lincomycin is not indicated for use in the treatment of meningitis as the levels within the cerebral spinal fluid do not reach an adequate concentration to combat this infection.
No serious renal or neurologic abnormalities have been reported to date. No ototoxicity has been demonstrated in any of a large number of patients treated with lincomycin.

Pregnancy: Limited experience with 322 women receiving lincomycin orally at a dosage of 500 mg 4 times/day for 7 days during pregnancy revealed no ill effect in the mother or the fetus. One hundred and ten of these patients were treated in the first trimester of pregnancy, 105 in the second trimester and 107 in the third trimester. All were suffering from cervicitis and/or vaginitis of bacterial origin in conjunction with their pregnancy. One hundred and twelve of the children, ages 6 1/2 to 7 1/2 years, from these patients have been examined and compared with a control group of 65 children born at the same time in the same hospital. Lincomycin treatment did not result in any drug related abnormalities (physical, dental or developmental) when compared with the control group.

Since safe conditions for the parenteral use of lincomycin in pregnancy have not been established, its use in such patients should involve careful consideration of expected benefits and possible risks.
Lactation: Lincomycin has been reported in breast milk at concentrations of 0.5 to 2.4 µg/mL.
Patients with Special Diseases and Conditions: The serum half-life of lincomycin is increased in those patients with impaired renal or hepatic function. Therefore, consideration should be given to reducing the frequency of administration in these patients.

Since adequate data are not yet available in patients with pre-existing endocrine or metabolic diseases, its use in such patients is not recommended at this time unless special clinical circumstances so indicate. Efficacy of lincomycin in the prophylactic treatment of rheumatic fever has not been established.

Dosage
As per physician’s advice.

Presentations
10 caps.
 

 


Note : This product information is intended only for residents of the India. Taj Pharmaceuticals Limited,  medicines help to treat and prevent a range of conditions—from the most common to the most challenging—for people around the world.

Information for Health Care Professionals

*** Please consult local Prescribing Information for any product before use. This website is an international information resource for healthcare professionals with an interest in disease management. This website is not intended to replace the advice of a qualified healthcare professional. Above brand is a trademark of the Taj group of companies (Taj Pharmaceuticals Limited)

 



Lincozin tablets

 









 

 

 

 

 

 

 

 

 

 

 

 

 

              
 Print page   Send by mail
 





 

   
   
PRODUCTS
 
 
   
   
   
  india flag
  The Taj Pharmaceuticals Limited (Taj Group) has operations in every major international market
    AFRICA
  ASIA PACIFIC
  EUROPE
  MIDDLE EAST
  THAILAND
  BANGLADESH
  NORTH AMERICA
  SOUTH AMERICA
  RUSSIA
  NEWZELAND
  UNITED KINGDOM
 

   

 

 

 

 

 

 

 

 

 

 

 

 

 


 

 
 www.tajpharma.com

   

 

About Taj

Company

Products Diseases Health Divisions Media R & D Sustainability
Figure & Reports Investors

Countries

Brochure E-mail us Export & Import
Vacancies | C & F Agency | Distributor | Group Companies | History | Enquire Form | Countries | Pharma Technology
 Contact | Sitemap | User Terms and Conditions | Privacy and Cookie Statement